AlphAIAlphAI — Financial news for AI agents
SEC EDGARJUN 241 min read$INSM

Smith Michael Alexander sold $173K of INSM

Smith Michael Alexander (Chief Legal Officer) sold 1,806 shares of INSMED Inc (INSM) at $95.82 ($0.17M total) on 2026-06-22 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Smith Michael Alexander
Published Jun 24, 2026, 4:00 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 6, 2026, 6:51 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$INSM
Neutral
medium confidence
Mentioned
$INSM
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$INSMNeutralLow
01

Why it matters

The disclosure confirms an officer-level open-market sale of $173,050.92 worth of INSM shares, executed under a pre-arranged 10b5-1 plan.

02

Market read

This is a routine insider sale filing with limited incremental information for trading decisions.

03

What to watch

Traders may over-weight single insider sales; the more informative signal would be repeated sales across multiple insiders or changes in plan parameters, which are not provided here.

Relevance 3/10Novelty 3/10Timing: filed 2026-06-24, sale dated 2026-06-22

Background

The article is an SEC Form 4 insider transaction disclosure for INSMED Inc.

Company-level read

Ticker impact

$INSMNeutralMedium confidence
Context

INSMED Form 4 shows Chief Legal Officer Michael Alexander sold 1,806 shares at $95.82 under a 10b5-1 plan.

Expected impact

Likely minimal, short-lived impact unless follow-on selling accelerates.

Evidence & confidence

The filing is a scheduled open-market sale under a pre-arranged 10b5-1 plan, which typically reduces interpretive value versus discretionary sales.

Market effects

Sector

No sector-level implications; this is company-specific insider transaction disclosure.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Because it is a 10b5-1 plan, the sale may reflect liquidity/compensation mechanics rather than bearish expectations.

Key entities

  • issuer
    INSMED Inc

    Company whose insider transaction is disclosed on Form 4.

  • insider
    Michael Alexander Smith

    Chief Legal Officer who sold shares.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

INSM insider trading history →

Related articles

SEP 28
$INSMMedAI 8/10

Insmed (INSM) Gets Faster FDA Review. Can Its Lung Drug Reach More Patients?

Insmed (INSM) announced the FDA granted priority review for its ARIKAYCE lung drug, setting a January 2027 decision date. The application seeks full approval for broader use in treating MAC lung disease. Clinical trial results showed significant improvements in respiratory symptoms and bacterial conversion rates. Success could expand the patient pool and increase revenue, but regulatory, tolerability, and commercialization risks remain.

insidermonkey.com2 min
SEP 22
$INSMHighAI 8/10

FDA Accepts Insmed's Filing Seeking Label Expansion for Arikayce

Insmed (INSM) announced the FDA accepted its filing for Arikayce's label expansion to treat newly diagnosed MAC lung disease, with a decision expected by Jan. 28, 2027. The filing is supported by positive phase IIIb ENCORE study results. Arikayce sales grew 7% YoY to $214.4M in H1 2026, with full-year sales projected at $450M-$470M. The expansion could significantly increase Arikayce's market potential, according to the company.

zacks.com2 min
SEP 21
HighAI 8/10

Why is Insmed stock climbing today?

Insmed stock rose 2.0% in pre-market trading after the FDA accepted and granted Priority Review to its sNDA for ARIKAYCE, targeting a decision by January 28, 2027. The application seeks full approval for the drug, backed by Phase 3b ENCORE study results. Full approval would expand ARIKAYCE's use to newly diagnosed patients and those with recurrent infections. Insmed also plans to engage Japan's pharmaceutical regulator in Q4 2026 for potential label expansion.

investing.com2 min
SEP 21
$INSMHighAI 8/10

Insmed stock rises on FDA priority review for Arikayce

Insmed Inc. (NASDAQ:INSM) shares rose 2% premarket after the FDA granted priority review to its sNDA for Arikayce, targeting MAC lung disease. The FDA set a review deadline of January 28, 2027. Arikayce, approved in 2018, could see expanded use if the application succeeds. The sNDA is backed by Phase 3b ENCORE study results showing significant improvements in respiratory symptoms and culture conversion.

investing.com1 min